ACTINIUM PHARMACEUTICALS INC's ticker is ATNM and the CUSIP is 00507W206. A total of 73 filers reported holding ACTINIUM PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $110,438 | +3.2% | 14,924 | +9.2% | 0.00% | – |
| Q1 2024 | $107,013 | +69.3% | 13,667 | +9.8% | 0.00% | – |
| Q4 2023 | $63,210 | -0.3% | 12,443 | +16.2% | 0.00% | – |
| Q3 2023 | $63,385 | -46.9% | 10,707 | -33.5% | 0.00% | – |
| Q2 2023 | $119,469 | +130.9% | 16,101 | +194.0% | 0.00% | – |
| Q1 2023 | $51,748 | -11.2% | 5,476 | +0.1% | 0.00% | – |
| Q4 2022 | $58,277 | +57.5% | 5,472 | +8.0% | 0.00% | – |
| Q3 2022 | $37,000 | +48.0% | 5,067 | +0.2% | 0.00% | – |
| Q2 2022 | $25,000 | -3.8% | 5,059 | +0.5% | 0.00% | – |
| Q1 2022 | $26,000 | -13.3% | 5,036 | +0.0% | 0.00% | – |
| Q4 2021 | $30,000 | -38.8% | 5,035 | -8.6% | 0.00% | – |
| Q3 2021 | $49,000 | +308.3% | 5,510 | +255.7% | 0.00% | – |
| Q2 2021 | $12,000 | +9.1% | 1,549 | +12.7% | 0.00% | – |
| Q1 2021 | $11,000 | -91.9% | 1,374 | -92.1% | 0.00% | – |
| Q4 2020 | $136,000 | +2166.7% | 17,380 | +2954.5% | 0.00% | – |
| Q3 2020 | $6,000 | – | 569 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Interchange Capital Partners, LLC | 11,420 | $90,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 47,097 | $373,000 | 0.04% |
| GOODWIN DANIEL L | 10,000 | $80,000 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 99,166 | $784,000 | 0.01% |
| EMFO, LLC | 1,666 | $13,000 | 0.01% |
| PINNACLE ASSOCIATES LTD | 34,333 | $272,000 | 0.01% |
| Hartford Financial Management Inc. | 598 | $5,000 | 0.00% |
| Global Financial Private Client, LLC | 266 | $2,059 | 0.00% |
| BLAIR WILLIAM & CO/IL | 51,466 | $407,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,808 | $30,000 | 0.00% |